Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease
We have compared the efficacy of two Leishmania (Leishmania) major vaccines, one genetically attenuated (DHFR-TS deficient organisms), the other inactivated [autoclaved promastigotes (ALM) with bacillus Calmete-Guérin (BCG)], in protecting rhesus macaques (Macaca mulatta) against infection with virulent L. (L.) major. Positive antigen-specific recall proliferative response was observed in vaccinees (79% in attenuated parasite-vaccinated monkeys, versus 75% in ALM-plus-BCG-vaccinated animals), although none of these animals exhibited either augmented in vitro gamma interferon (IFN-<FONT FACE=Symbol>g</font>) production or positive delayed-type hypersensitivity (DTH) response to the leishmanin skin test prior to the challenge. Following challenge, there were significant differences in blastogenic responses (p < 0.05) between attenuated-vaccinated monkeys and naïve controls. In both vaccinated groups very low levels of antibody were found before challenge, which increased after infective challenge. Protective immunity did not follow vaccination, in that monkeys exhibited skin lesion at the site of challenge in all the groups. The most striking result was the lack of pathogenicity of the attenuated parasite, which persisted in infected animals for up to three months, but were incapable of causing disease under the conditions employed. We concluded that both vaccine protocols used in this study are safe in primates, but require further improvement for vaccine application.
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Instituto Oswaldo Cruz, Ministério da Saúde
2002
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762002000700019 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0074-02762002000700019 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0074-027620020007000192002-12-04Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human diseaseAmaral,VFTeva,AOliveira-Neto,MPSilva,AJPereira,MSCupolillo,EPorrozzi,RCoutinho,SGPirmez,CBeverley,SMGrimaldi Jr,G Leishmania (L.) major rhesus macaques (Macaca mulatta) vaccination attenuated and killed promastigotes bacillus Calmete-Guerin (BCG) We have compared the efficacy of two Leishmania (Leishmania) major vaccines, one genetically attenuated (DHFR-TS deficient organisms), the other inactivated [autoclaved promastigotes (ALM) with bacillus Calmete-Guérin (BCG)], in protecting rhesus macaques (Macaca mulatta) against infection with virulent L. (L.) major. Positive antigen-specific recall proliferative response was observed in vaccinees (79% in attenuated parasite-vaccinated monkeys, versus 75% in ALM-plus-BCG-vaccinated animals), although none of these animals exhibited either augmented in vitro gamma interferon (IFN-<FONT FACE=Symbol>g</font>) production or positive delayed-type hypersensitivity (DTH) response to the leishmanin skin test prior to the challenge. Following challenge, there were significant differences in blastogenic responses (p < 0.05) between attenuated-vaccinated monkeys and naïve controls. In both vaccinated groups very low levels of antibody were found before challenge, which increased after infective challenge. Protective immunity did not follow vaccination, in that monkeys exhibited skin lesion at the site of challenge in all the groups. The most striking result was the lack of pathogenicity of the attenuated parasite, which persisted in infected animals for up to three months, but were incapable of causing disease under the conditions employed. We concluded that both vaccine protocols used in this study are safe in primates, but require further improvement for vaccine application.info:eu-repo/semantics/openAccessInstituto Oswaldo Cruz, Ministério da SaúdeMemórias do Instituto Oswaldo Cruz v.97 n.7 20022002-10-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762002000700019en10.1590/S0074-02762002000700019 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Amaral,VF Teva,A Oliveira-Neto,MP Silva,AJ Pereira,MS Cupolillo,E Porrozzi,R Coutinho,SG Pirmez,C Beverley,SM Grimaldi Jr,G |
spellingShingle |
Amaral,VF Teva,A Oliveira-Neto,MP Silva,AJ Pereira,MS Cupolillo,E Porrozzi,R Coutinho,SG Pirmez,C Beverley,SM Grimaldi Jr,G Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease |
author_facet |
Amaral,VF Teva,A Oliveira-Neto,MP Silva,AJ Pereira,MS Cupolillo,E Porrozzi,R Coutinho,SG Pirmez,C Beverley,SM Grimaldi Jr,G |
author_sort |
Amaral,VF |
title |
Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease |
title_short |
Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease |
title_full |
Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease |
title_fullStr |
Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease |
title_full_unstemmed |
Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease |
title_sort |
study of the safety, immunogenicity and efficacy of attenuated and killed leishmania (leishmania) major vaccines in a rhesus monkey (macaca mulatta) model of the human disease |
description |
We have compared the efficacy of two Leishmania (Leishmania) major vaccines, one genetically attenuated (DHFR-TS deficient organisms), the other inactivated [autoclaved promastigotes (ALM) with bacillus Calmete-Guérin (BCG)], in protecting rhesus macaques (Macaca mulatta) against infection with virulent L. (L.) major. Positive antigen-specific recall proliferative response was observed in vaccinees (79% in attenuated parasite-vaccinated monkeys, versus 75% in ALM-plus-BCG-vaccinated animals), although none of these animals exhibited either augmented in vitro gamma interferon (IFN-<FONT FACE=Symbol>g</font>) production or positive delayed-type hypersensitivity (DTH) response to the leishmanin skin test prior to the challenge. Following challenge, there were significant differences in blastogenic responses (p < 0.05) between attenuated-vaccinated monkeys and naïve controls. In both vaccinated groups very low levels of antibody were found before challenge, which increased after infective challenge. Protective immunity did not follow vaccination, in that monkeys exhibited skin lesion at the site of challenge in all the groups. The most striking result was the lack of pathogenicity of the attenuated parasite, which persisted in infected animals for up to three months, but were incapable of causing disease under the conditions employed. We concluded that both vaccine protocols used in this study are safe in primates, but require further improvement for vaccine application. |
publisher |
Instituto Oswaldo Cruz, Ministério da Saúde |
publishDate |
2002 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762002000700019 |
work_keys_str_mv |
AT amaralvf studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease AT tevaa studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease AT oliveiranetomp studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease AT silvaaj studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease AT pereirams studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease AT cupolilloe studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease AT porrozzir studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease AT coutinhosg studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease AT pirmezc studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease AT beverleysm studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease AT grimaldijrg studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease |
_version_ |
1756383432374484992 |